A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Administered By

Awarded By

Contributors

Start/End

  • December 15, 2016 - December 14, 2021